Compass Therapeutics Concludes Enrollment In COMPANION-002 With CTX-009

Compass Therapeutics, a biopharmaceutical company specializing in oncology and focused on developing unique antibody-based treatments for various diseases, has announced that it has successfully enrolled 150 patients in its COMPANION-002 clinical trial. This randomized Phase 2/3 trial is assessing the effectiveness of CTX-009 in patients with BTC.

Thomas Schuetz, MD, PhD, Co-founder, CEO, and Vice Chairman of the Compass Board of Directors, said “We are very pleased to announce this enrollment milestone for the COMPANION-002 trial. We extend our deep gratitude to all the patients, families, and caregivers who are participating in the study. We would also like to thank the principal investigators, study coordinators, the Cholangiocarcinoma Foundation, and the clinical team at Compass for their dedicated support and hard work.”

Significantly, the Company has received approval for a new Investigator-Sponsored Trial (IST) to investigate CTX-009 in patients with BTC undergoing first-line treatment. This study will take place at The University of Texas MD Anderson Cancer Center, where CTX-009 will be incorporated into the standard first-line therapy regimen, which includes gemcitabine, cisplatin, and durvalumab. Dr. Schuetz further added, “Following completion of enrollment in COMPANION-002, our second-line study, we are very excited to advance CTX-009 to the first-line setting in collaboration with our investigators at MD Anderson.”